ImClone Investigational Site

Seattle, Washington 98109

0 studies enrolling now · 15 studies all time

What they study most

Adenocarcinoma of the Prostate, Advanced Solid Tumors, Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Malignant Solid Tumor, Metastatic Malignant Melanoma, Metastatic Renal Cell Carcinoma, Non Small Cell Lung Cancer, Ovarian Cancer

Studies at this site

• A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors — Completed
• Study of Ramucirumab in Ovarian Cancer — Completed
• A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma — Completed
• A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available — Completed
• Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer — Completed
• A Study of Olaratumab in Soft Tissue Sarcoma — Completed
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib — Completed
• Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes — Completed
• A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer — Completed
• A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma — Completed
• A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma — Stopped early